Literature DB >> 16368477

Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin.

Brian T Tsuji1, Michael J Rybak.   

Abstract

In search for potential synergistic antimicrobial combinations against Staphylococcus aureus isolates, which display heterogeneous resistance to vancomycin, we evaluated the activities of 21 various combinations involving ampicillin/sulbactam, daptomycin, gentamicin, linezolid, quinupristin/dalfopristin, rifampin, and vancomycin by Etest and time-kill methods. A number of combinations demonstrated either synergistic or additive effects against hGISA SA118 and GISA SA179. Agreement between the Etest and time-kill methods for detecting antimicrobial synergy ranged from 66.6% to 71.4%. The Etest method appears promising, and further investigations are warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16368477     DOI: 10.1016/j.diagmicrobio.2005.08.014

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  13 in total

Review 1.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

2.  In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid.

Authors:  B Hellmark; M Unemo; A Nilsdotter-Augustinsson; B Söderquist
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-03-12       Impact factor: 3.267

Review 3.  New antimicrobial agents as therapy for resistant gram-positive cocci.

Authors:  J R Lentino; M Narita; V L Yu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01       Impact factor: 3.267

Review 4.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

5.  Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.

Authors:  Xuting Zheng; Andrew D Berti; Sue McCrone; Melanie Roch; Adriana E Rosato; Warren E Rose; Baiyi Chen
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.

Authors:  Kristina Nadrah; Franc Strle
Journal:  Chemother Res Pract       Date:  2011-04-18

Review 7.  Bacteriocin-Antimicrobial Synergy: A Medical and Food Perspective.

Authors:  Harsh Mathur; Des Field; Mary C Rea; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Front Microbiol       Date:  2017-06-29       Impact factor: 5.640

8.  Update on the appropriate use of linezolid in clinical practice.

Authors:  Roberto Manfredi
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

9.  Daptomycin-Nonsusceptible Staphylococcus aureus: The Role of Combination Therapy with Daptomycin and Gentamicin.

Authors:  Jhih-Hang Jiang; Anton Y Peleg
Journal:  Genes (Basel)       Date:  2015-11-30       Impact factor: 4.096

10.  CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.

Authors:  Steven Y C Tong; Jane Nelson; David L Paterson; Vance G Fowler; Benjamin P Howden; Allen C Cheng; Mark Chatfield; Jeffrey Lipman; Sebastian Van Hal; Matthew O'Sullivan; James O Robinson; Dafna Yahav; David Lye; Joshua S Davis
Journal:  Trials       Date:  2016-03-31       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.